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Abstract
Background/objective: This study was designed to evaluate the potential chemopreventive activities of Ginkgo
biloba extract (EGb) and Silybum marianum extract (silymarin) against hepatocarcinogenesis induced by N-
nitrosodiethylamine (NDEA) in rats.
Methods: Rats were divided into 6 groups. Group 1 served as normal control rats. Group 2 animals were
intragastrically administrated NDEA at a dose of 10 mg/kg five times a week for 12 weeks to induce
hepatocellular carcinoma (HCC). Groups 3 and 4 animals were pretreated with silymarin and EGb respectively.
Groups 5 and 6 animals were posttreated with silymarin and EGb respectively. The investigated parameters in
serum are alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyltransferase (GGT)
and vascular endothelial growth factor (VEGF). The investigated parameters in liver tissue are malondialdehyde
(MDA), glutathione (GSH), superoxide dismutase (SOD), glutathione peroxidase (GPx), glutathione reductase (GR)
and comet assay parameters.
Results: In NDEA group, MDA level was elevated with subsequent decrease in GSH level and SOD, GPx and GR
activities. In addition, NDEA group revealed a significant increase in serum ALT, AST and GGT activities and VEGF
level. Furthermore, NDEA administrated animals showed a marked increase in comet assay parameters. These
biochemical alterations induced by NDEA were confirmed by the histopathological examination of rat livers
intoxicated with NDEA that showed an obvious cellular damage and well differentiated HCC.
In contrast, silymarin+NDEA treated groups (3&5) and EGb+NDEA treated groups (4&6) showed a significant
decrease in MDA level and a significant increase in GSH content and SOD, GPx and GR activities compared to
NDEA group. Silymarin and EGb also beneficially down-regulated the increase in serum ALT, AST, GGT activities and
VEGF level induced by NDEA. In addition, silymarin and EGb significantly decreased comet assay parameters.
Histopathological examination of rat livers treated with either silymarin or EGb exhibited an improvement in the
liver architecture compared to NDEA group.
Conclusions: The obtained findings suggested that silymarin and EGb may have beneficial chemopreventive roles
against hepatocarcinogenesis through their antioxidant, antiangiogenic and antigenotoxic activities.
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Hepatocellular carcinoma is the fifth most common can-
cer worldwide and the third most common cause of
cancer mortality with a continuously increasing inci-
dence annually [1]. The major known risk factors for
HCC are viral (chronic hepatitis B and hepatitis C),
toxic (alcohol and aflatoxins), metabolic (diabetes and
non alcoholic fatty liver disease, hereditary haemochro-
matosis), immune related (primary biliary cirrhosis and
autoimmune hepatitis), food additives, environmental
and industrial toxic chemicals and air and water pollu-
tants [2]. In Egypt, between 1993 and 2002, there was
an almost two-fold increase in HCC amongst chronic
liver patients [3]. It has been found that hepatitis C
virus (HCV) and schistosomiasis play a major role in
the development of HCC in Egypt where the highest
prevalence of HCV in the world which has been attribu-
ted to previous public health eradication schemes for
schistosomiasis [4,5]. Although there are many strategies
for the treatment of HCC [6], its therapeutic outcome
remains very poor. Therefore, preventive strategies are
of paramount importance and need to be actively
explored in order to reduce the incidence of this disease.
The reduced cancer risk and lack of toxicity associated
with high intake of natural products suggest that specific
concentrations of phytochemicals from these plant
sources may produce cancer chemopreventive effects
without causing significant levels of toxicity. These nat-
ural products are believed to suppress the inflammatory
process that lead to neoplastic transformation, hyperpro-
liferation, promotion and progression of carcinogenic
process and angiogenesis [7].
Silymarin, a standardized extract from Silybum maria-
num (milk thistle; a medicinal plant), has been exten-
sively studied and has shown anticancer efficacy against
various cancer sites [8,9]. This has been attributed to
that silymarin interfers with the expression of cell cycle
regulators and proteins involved in apoptosis. Addition-
ally, silymarin has antioxidant properties and anti-meta-
static activity [10]. Several studies have shown that
silymarin has tumor suppressive effect on hepatocarci-
nogenesis [11-13].
Ginkgo biloba, a unique tree, is one of the best known
examples of a living fossil. Ginkgo leaf extract has
powerful anti-cancer properties through its antioxidant,
gene-regulatory and antiangiogenic properties [14].
Ginkgo biloba extract may regulate cell proliferation and
induce apoptosis of human hepatocellular cell lines:
HepG2, Hep3B, and SMMC-7721 cells, therefore it may
have protective effects against hepatocarcinogenesis
[15,16].
In the present study, we investigated the chemopre-
ventive effects of Ginkgo biloba and Silybum marianum
extracts as antioxidant, antiangiogenic and antigenotoxic
substances against HCC induced by NDEA in experi-
mental animals. This may be promising at stopping
hepatocarcinogenesis, delaying its progress, minimizing
the damage to liver cells or reducing its complications.
Materials and methods
Animals
Healthy male Wistar albino rats weighing 100-120 g
supplied from the animal house of National Research
Center (Dokki, Giza, Egypt) were used for this study.
Animals were housed in cages under proper environ-
mental conditions at room temperature 22-24°C and 12
h light/dark cycle and fed with a commercial pellet diet
(Wadi El Kabda Co., Cairo, Egypt). The animals had
free access to water. The animals were acclimatized to
the laboratory conditions for two weeks before begin-
ning the experiment. The experiment continued for 13
weeks on which constant weight of diet was given for
each rat. All the experiments were designed and con-
ducted according to the ethical norms approved by the
Ethical Committee of National Research Center.
Chemicals
N-nitrosodiethylamine and ethidium bromide were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA), vas-
cular endothelial growth factor ELISA kit was purchased
from RayBiotech, Inc. (Milford, MA, USA), AST and
ALT kits were purchased from Stanbio laboratory
(Boerne, TX, USA) and GGT kit was purchased from
Centronic GmbH (Wartenberg, Germany). Silymarin
was purchased from ACAPI Co. (Cairo, Egypt). Sily-
marin consists of 80% w/w of silybin with smaller
amounts of isosilybin, dihydrosilybin, silydianin, and
silychristin. EGb was purchased from EMA Pharm Co.
(Cairo, Egypt). EGb consists of approximately 24% fla-
vone glycosides (quercetin, kaempferol and isorhamne-
tin), 6% terpene trilactones (ginkgolides A, B and C,
bilobalide) and less than 5 ppm ginkgolic acid. All the
other chemicals used were of high analytical grade and
were purchased locally.
Experimental design
The experimental animals were divided into six groups (as
shown in figure 1); each group was comprised of eight ani-
mals except group 2 which was comprised of 12 animals
(4 rats were used for the confirmation of the induction of
HCC at the end of 9
th week of the experiment by the his-
topathological examination of rat livers). Group 1: Normal
control rats fed with standard diet for 13 weeks. Group 2:
Rats were induced with HCC by NDEA received intragas-
trically at a dose of 10 mg/kg body weight 5 times a week
for 12 weeks [17]. Group 3: Rats pretreated with silymarin
(100 mg/kg body weight daily) received intragastrically
one week before the administration of NDEA and
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[18]. Group 4: Rats pretreated with EGb (100 mg/kg body
weight daily) received intragastrically one week before the
administration of NDEA and continued till the end of the
experiment [19]. Group 5: Rats posttreated with silymarin
(100 mg/kg body weight daily) received intragastrically for
4 weeks after the administration of NDEA for 8 weeks and
continued till the end of experiment [18]. Group 6: Rats
posttreated with EGb (100 mg/kg body weight daily)
received intragastrically for 4 weeks after the administra-
tion of NDEA for 8 weeks and continued till the end of
experiment [19]. At the end of experimental period, the
animals were fasted overnight then subjected to mild ether
anesthesia and blood samples were collected. The blood
was allowed to coagulate and centrifuged at 3000 rpm for
15 minutes at 4°C to separate the serum to be used for
biochemical analysis. After blood collection, rats were dis-
sected then the livers were excised and small sections
were cut with cold knife. The first liver section was used
for the preparation of the liver tissue homogenate to be
used for the biochemical tissue analysis. The second liver
section was used for the histopathological examination.
The third liver section was used for the comet assay.
Biochemical analysis
1. Determination of liver function enzymes
ALT and AST activities were determined in the sera of
rats using Stanbio kit following the method described by
Bergmeyer et al. [20]. GGT was measured in the sera
of rats using Centronic GmbH- Germany Kit following
the method described by Persijn and van der Slik [21].
2. Determination of hepatic reduced glutathione, lipid
peroxidation and antioxidant enzymes
The hepatic GSH content was estimated by the method
of Beutler et al. [22]. Lipid peroxidation was measured
in the liver tissue as MDA level according to the
method of Ruiz-Larrea et al. [23]. Glutathione reduc-
tase (GR) activity was assayed in the liver tissue accord-
ing to the method of Erden and Bor [24]. Glutathione
peroxidase (GPx) activity was estimated in the liver tis-
sue by the method of Paglia and Valentine [25]. Super-
oxide dismutase (SOD) activity in the liver tissue was
measured by the method of Nishikimi et al. [26]. Total
proteins were assayed in the liver tissue according to the
method of Bradford [27].
3. Determination of vascular endothelial growth factor
(VEGF)
The measurement of VEGF in the sera of rats using
ELISA technique according to the method of Ferrara
[28] using rat VEGF ELISA kit, ELISA (Dynatech MR
5000, Midland, ON, Canada), Washer (Dynatech MRW,
Gaithersburg, MD, USA), Shaker (Varishaker-Incupator,
NJ, USA) and Printer (Panasonic Quiet KXP2123, Seri
Kembangan, Selangor, Malaysia).
Comet assay (single cell gel electrophoresis, SCGE)
DNA damage was measured using the comet assay
under alkaline conditions and dim indirect light. The
Figure 1 The experimental design diagram.
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some modifications [29]. The liver was excised, washed
in saline solution and a small fragment of the liver was
transferred to a Petri dish kept on ice. The fragment was
washed, minced and suspended into 1 ml cold Hank’s
balanced salt solution (HBSS) containing 20 mM EDTA
and 10% dimethylsulphoxide (DMSO). The fragment was
cut into smaller pieces using a disposable microtome
razor blade and the solution was aspirated. A fresh min-
cing solution was added and the liver samples were
minced again into finer pieces. The suspension contain-
ing isolated cells was transferred to a tube maintained on
ice until the preparation of the slides [30]. The quantity
of liver cells in the cell suspensions was determined in
Giemsa-stained smears. From the liver cell suspension
containing approximately 2 × 10
4-5 × 10
4 cells/ml, 5 μl
was removed and mixed with 95 μl of 0.5% low melting
point agarose; LMPA (in Ca
+2 and Mg
+2 free PBS) to pre-
pare the final cell-agarose suspension. From the final cell-
agarose suspension, 80 μl was spread over the micro-
scope slide (75 × 25 mm glass slides with 19 mm frosted
ends, Gibco-BRL), pre-coated with 1% normal melting
p o i n ta g a r o s e ;N M P A( G i b c o - B R L ) .T h ec e l l sw e r et h e n
lysed in freshly prepared buffer containing 2.5 M NaCl,
100 mM EDTA, 10 mM Tris (pH 10.0), 1% Triton X-100
and 10% DMSO for 24 h at 4°C. After lysis, the slides
were rinsed three times in deionized water to remove salt
and detergent. The slides were placed in a horizontal
electrophoresis unit (Cleaver Scientific Ltd, UK) and
DNA was allowed to unwind for 20 min in alkaline solu-
tion containing 300 mM NaOH and 1 mM EDTA, pH >
13. The DNA was electrophoresed for 20 min at 300 mA
and 30 V (0.90 V/cm). The slides were then neutralized
with 0.4 m Tris (pH 7.5), fixed for 5 min in absolute alco-
hol, air-dried and stored at room temperature. Immedi-
ately before analysis, the DNA was stained with 50 μl
ethidium bromide (20 μg/ml).
Data scoring and photomicrographs
The fluorescent labeled DNA was visualized (magnifica-
tion 400x) using an automated fluorescence microscope
(Carl Zeiss, Germany) and the images were captured on
a computer, equipped with CometScore software
(Komet IV). Three parameters were adopted as indica-
tors of DNA damage: tail length (TL in μm),% DNA in
comet tail (% DNA in tail) and tail moment (TM in
arbitrary units, TM = TL X% DNA in tail).% DNA in
tail is the most preferred parameter because it covers a
wide range of damage and is linearly related to the
break frequency [31].
Histopathological examination
Tissue specimens from liver were collected from all
experimental groups at the end of experiment and fixed
in neural buffered formalin 10%, dehydrated in ascending
concentration of ethanol, cleared in xylene and
embedded in paraffin. Sections 4-5 μm in thickness were
prepared and stained with Hematoxylin and Eosin [32].
Statistical analysis
The data obtained was statistically analyzed using SPSS
software package (version 7.5). Hypothesis testing methods
included one way analysis of variance (ANOVA) followed
by least significant differences (LSD). Values are expressed
as mean ± S.D. P value ≤ 0.05 was considered significant.
Results
Confirmation of the induction of HCC in rats
During the experiment, we dissected four rats from
NDEA treated group at the end of 9
th week of experi-
ment (i.e the end of 8
th week of NDEA administration)
and liver was examined histopathologically. The histo-
pathological examination of the liver revealed that HCC
was induced.
Effect of silymarin and EGb on hepatic MDA, GSH and
antioxidant enzymes
A significant increase in MDA level was observed in
NDEA treated rats compared to control rats (table 1).
Prophylactic treatment with either silymarin or EGb for
13 weeks showed a significant protection against NDEA
induced lipid peroxidation (table 1). Therapeutic treat-
ment with either silymarin or EGb for 4 weeks offered a
significant decrease in MDA level compared to NDEA
treated rats (table 1). NDEA administration led to a sig-
nificant depletion in hepatic GSH content compared with
control rats (table 1). Pretreatment and posttreatment
with either silymarin or EGb significantly improved hepa-
tic GSH level compared to NDEA group (table 1). The
activities of hepatic antioxidant enzymes; GR, GPx and
SOD were significantly decreased in NDEA group com-
pared with control animals (table 1). The pretreated and
posttreated groups with either silymarin or EGb showed
a significant increase in hepatic GR, GPx and SOD activ-
ities compared to NDEA intoxicated group (table 1).
Effect of silymarin and EGb on serum transaminases and
gamma glutamyltransferase
The activities of serum ALT, AST and GGT were signif-
icantly increased in NDEA treated group compared to
control group (table 2). Pretreatment and posttreatment
with either silymarin or EGb significantly reduced the
elevation in the serum ALT, AST and GGT activities
induced by NDEA administration (table 2).
Effect of silymarin and EGb on serum VEGF
The serum VEGF level in NDEA group showed the
most highly significant elevation compared to control
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Page 4 of 12Table 1 Hepatic MDA, GSH levels, GR, GPx and SOD activities in different experimental groups
Groups MDA
(nmol MDA/g tissue)
GSH
(mg/g tissue)
GR
(nmol NADPH reacted/min/mg protein)
GPx
(nmol NADPH reacted/min/mg protein)
SOD
(nmol NADPH reacted/min/mg protein)
Control 11.65 ± 1.10 6.86 ± 1.21 85.94 ± 5.74 102.26 ± 8.43 49.34 ± 3.08
NDEA 22.97 ± 2.79
a 0.43 ± 0.10
a 51.94 ± 2.88
a 18.34 ± 3.49
a 5.28 ± 0.82
a
Pre S.m 13.89 ± 1.89
b 3.38 ± 0.16
b 72.44 ± 3.91
b 25.26 ± 2.76
b 37.04 ± 4.76
b
Pre G.b 14.42 ± 1.56
b 4.54 ± 1.00
b 77.27 ± 13.15
b 36.63 ± 4.10
b 32.28 ± 3.23
b
Post S.m 16.74 ± 2.90
b,c 2.36 ± 0.45
b,c 62.51 ± 5.50
b,c 20.00 ± 1.67
c 17.39 ± 2.40
b,c
Post G.b 17.53 ± 3.32
b,d 3.64 ± 0.57
b,d 61.47 ± 6.42
b,d 29.84 ± 2.92
b,d 20.92 ± 1.77
b,d
Results are given as mean ± S.D. for 6 rats. Pre S.m = Pretreated silymarin, Pre G.b = Pretreated EGb, Post S.m = Posttreated silymarin, Post G.b = Posttreated EGb. a: significantly different from control group at p ≤
0.05. b: significantly different from NDEA group at p ≤ 0.05. c: significantly different from Pre S.m group at p ≤ 0.05. d: significantly different from Pre G.b group at p ≤ 0.05.
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2rats (figure 2). All treated groups with either sily-
marin or EGb showed a significant reduction in
serum VEGF level compared to NDEA intoxicated
group (figure 2).
Effect of silymarin and EGb on DNA damage
A significant increase in different comet assay para-
meters (TL,% DNA in tail and TM) has been shown in
animals receiving NDEA compared with the negative
control animals (figure 3). Prophylactic and therapeutic
treatment with either silymarin or EGb significantly
reduced NDEA induced DNA damage as indicated by
reduction in different comet assay parameters (TL,%
DNA in tail and TM) (figure 3). Photomicrographs of
comets in the hepatocytes stained with ethidium bro-
mide in different experimental groups are illustrated in
figure (4).
Effect of silymarin and EGb on liver histopathology
Histopathological examination of liver sections from
control group revealed normal architecture (figure 5a).
While, liver sections of NDEA administered animals
revealed well differentiated HCC with apoptosis of hepa-
tocytes, mitotic figures, megalocytosis, foamy cytoplasm
and hyperchromatic nuclei (figure 5b). Liver sections of
rats pretreated with either silymarin or EGb restored
many of normal hepatic architecture with less disar-
rangement and degeneration of hepatocytes, minimal
nuclear vesiculation and nuclear prominence compared
with NDEA treated group (figure 5c,d). Meanwhile, liver
sections of rats posttreated with either silymarin or EGb
revealed slight improvement in the hepatocytes com-
pared with NDEA treated group. Liver sections of rats
posttreated with silymarin revealed lesser degree of cyto-
megalic and vacuolated hepatocytes with minimal
nuclear vesiculation and nuclear prominence compared
to HCC-induced animals (figure 5e). The proliferation
of oval cells had been also observed (figure 5e). Liver
sections of rats posttreated with EGb revealed lesser
degree of vacuolated hepatocytes and kupffer cells acti-
vation compared with NDEA treated group (figure 5f).
Discussion
N-nitrosodiethylamine, as a well known potent hepato-
carcinogenic agent, may be present in tobacco smoke,
water, cured and fried meals, cheddar cheese, agricul-
tural chemicals, cosmetics and pharmaceutical products.
It is also found in minute concentrations in baby bottle
nipples [33]. Metabolism of certain therapeutic drugs is
also reported to produce NDEA [34].
Figure 2 Serum VEGF level of the rats of different experimental groups. Results are given as mean ± S.D. for 6 rats. a: significantly different
from control group at p ≤ 0.05. b: significantly different from NDEA group at p ≤ 0.05. c: significantly different from silymarin pretreated group
at p ≤ 0.05. d: significantly different from Ginkgo biloba pretreated group at p ≤ 0.05.
Table 2 Effect of silymarin and Ginkgo biloba extract on
ALT, AST and GGT activities in the sera of rats of
different experimental groups
Groups ALT(U/L) AST(U/L) GGT(U/L)
Control 23.05 ± 1.68 62.47 ± 3.65 31.68 ± 4.38
NDEA 75.20 ± 1.52
a 101.22 ± 2.66
a 87.84 ± 10.45
a
Pre S.m 41.43 ± 1.13
b 82.27 ± 1.54
b 53.02 ± 4.77
b
Pre G.b 36.09 ± 1.24
b 81.62 ± 3.05
b 53.29 ± 7.68
b
Post S.m 53.55 ± 2.48
b,
c 92.23 ± 6.24
b,
c 68.03 ± 5.36
b,
c
Post G.b 46.97 ± 2.09
b,
d 95.47 ± 3.71
b,
d 68.27 ± 8.39
b,
d
Results are given as mean ± S.D. for 6 rats. Pre S.m = Pretreated silymarin, Pre
G.b = Pretreated EGb, Post S.m = Posttreated silymarin, Post G.b = Posttreated
EGb. a: significantly different from control group at p ≤ 0.05. b: significantly
different from NDEA group at p ≤ 0.05. c: significantly different from Pre S.m
group at p ≤ 0.05. d: significantly different from Pre G.b group at p ≤ 0.05.
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administration of NDEA lead to induction of HCC and
augmentation of oxidative stress in livers of NDEA trea-
ted rats. NDEA impaired antioxidative defense as indi-
cated by a significant elevation in the level of oxidative
stress marker (MDA) and a significant depletion of free
radical scavenging antioxidants (GR, GPx, SOD and
GSH). The oxidative stress in livers of HCC-induced
rats may be attributed to that NDEA is mainly metabo-
lized in the liver by the action of cytochrome p450
enzymes and the reactive metabolites are primarily
responsible for its hepatotoxic effects. NDEA is
Figure 3 Comet assay parameters in the hepatic tissue of rats of different experimental groups. Results are given as mean ± S.D. for 4
rats. a: significantly different from control group at p ≤ 0.05. b: significantly different from NDEA group at p ≤ 0.05. c: significantly different from
silymarin pretreated group at p ≤ 0.05. d: significantly different from Ginkgo biloba pretreated group at p ≤ 0.05.
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bases to form promutagenic adducts such as O
6-ethyl-
deoxyguanosine and O
4 and O
6-ethyldeoxythymidine
and these ROS induce oxidative stress and cytotoxicity
by damaging biomolecules such as DNA, lipids and pro-
teins [35]. Depletion in GSH level and GSH dependent
enzymes, GPx and GR, in NDEA treated rats might be
attributed to the reduction in their biosynthesis during
hepatocellular damage or their excessive utilization in
scavenging the free radicals formed during the metabo-
lism of NDEA. Furthermore, the decreased levels of cel-
l u l a rG S Hm i g h th a v ec a u s e dar e d u c t i o ni nt h e
activities of GSH dependent enzymes, GPx and GR, as
GSH is a vital co-factor for these enzymes [11,36].
Supplementation of the extracts under investigation
(silymarin and EGb) to NDEA treated animals effectively
Figure 4 Photomicrographs of comets in the hepatocytes stained with ethidium bromide in different experimental groups. Control (a),
NDEA (b), Silymarin pretreated (c), EGb pre-treated (d), Silymarin post-treated (e) and EGb post-treated (f) (400x).
Figure 5 Histopathological photomicrographs of the liver of rats of different experimental groups. (a) Liver from control group showing
normal hepatic architecture with the central vein (CV) lying at the center of the hepatic lobule surrounded by the hepatocytes (H & E stain-X
400). (b) Liver from NDEA administrated group showing disorganization of hepatic lobular architecture and obvious cellular damage. The
hepatocytes lost their normal shape, lost their arrangement and showed megalocytosis (red arrow), hyperchromatic nuclei (blue arrow) as well as
nuclear vesiculation and nuclear prominence (black arrow) (H & E stain-X 400). (c) Liver from silymarin pretreated group showing Kupffer cells
proliferation (red arrow), minimal nuclear vesiculation and nuclear prominence (blue arrow) (H & E stain-X 400). (d) Liver from EGb pretreated
group showing hepatocytes with foamy cytoplasm (red arrow), minimal nuclear vesiculation and nuclear prominence (blue arrow) (H & E stain-X
400). (e) Liver from silymarin posttreated group showing oval cells proliferation (red arrow) (H & E stain-X 400). (f) Liver from EGb posttreated
group showing lesser degree of vacuolated hepatocytes (red arrow) (H & E stain-X 400).
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ker, MDA as well as the antioxidant indices, SOD, GR,
GPx and GSH implying the beneficial antioxidant abil-
ities of these extracts. Supporting our findings with sily-
marin, Ramakrishnan et al. [37] reported a significant
decrease in lipid peroxidation with a significant increase
in GSH level as well as an improvement in the activities
of the antioxidant enzymes, GR and GPx in the haemo-
lysate and the liver of silymarin treated animals com-
pared to NDEA treated animals. These revealed the
anti-lipid peroxidative activity of silymarin and its ability
to inhibit free radical generation. The increase in GSH
may reduce the DNA-carcinogen interaction by provid-
ing a large nucleophilic pool for electrophilic carcinogen
(NDEA). GSH neutralizes the electrophilic site by pro-
viding SH group and renders the metabolite more water
soluble [38]. It has been reported that there is an
improvement in the activities of the antioxidant
e n z y m e sa sN A D P Hr e q u i r e df o rt h ep r o d u c t i o no f
GSH is produced by the pentose phosphate pathway
[39]. Silymarin has the ability to increase the glucose
uptake in the cells which might enhance the levels of
glucose uptake by the cells that ultimately serves as fuel
for both pentose phosphate pathway and oxidative phos-
phorylation thereby bringing up the cellular levels of
NADPH/NADP
+. Increasing the levels of NADPH, GR
activity also is improved thereby raising the levels of the
GSH, the substrate for GPx [40]. Supporting our find-
ings with EGb, Naik and Panda [41] reported that EGb
significantly increased the activities of free radical
scavenging enzymes, SOD, GPx, GR and catalase and
the non-enzymatic antioxidant, GSH in CCl4-treated
rats compared with CCl4 treatment alone. Ginkgo biloba
extract inhibits lipid peroxidation by scavenging free
radicals and ROS maintaining the integrity and perme-
ability of cell membranes thereby protecting cells and
tissues against oxidative stress induced by the free radi-
cals [42]. These beneficial effects of EGb could be
explained not only by its antioxidant properties, but also
by its ability to inhibit the main cytochrome P450 isoen-
zyme 2E1 (CYP2E1) that metabolizes NDEA and CCl4
inducing ROS generation and lipid peroxidation [35,43].
Researchers recognize that tumor growth is angiogen-
esis-dependent and every increment of tumor growth
requires an increment of vascular growth. Tumors lack-
ing angiogenesis remain dormant indefinitely and rapid
logarithmic growth follows the acquisition of a blood
supply. Therefore, many researchers show great interests
in identifying and modulating antiangiogenic pathways
and developing antiangiogenic drugs for therapeutic
purposes [14,44]. VEGF is one of the most important
angiogenic cytokines. The overexpression of VEGF has
been shown to enhance tumor growth and its expres-
sion correlates with poor prognosis in several types of
tumors including HCC which is a typical hypervascular
tumor [45]. Data in the present study showed that the
serum VEGF level in NDEA treated rats was signifi-
cantly elevated compared to the normal healthy rats.
Liu et al. [46] reported that the expression of VEGF in
NDEA treated group was remarkably elevated and no
positive expression of VEGF was found in the negative
control group. These results might be attributed to the
high angiogenic activity in NDEA-induced hepatocarci-
noma rats, in addition to the increase of nitric oxide
activity in NDEA treated animals compared to the nega-
tive control animals, thus enhancing the angiogenesis by
stimulating the synthesis of VEGF [47]. Turlin et al.
[48] also reported an overexpression of VEGF in hepatic
foci and tumors in NDEA treated animals, this high
expression was associated with breakdown of the vascu-
lar wall by tumor cells. Since VEGF can act as a perme-
ability factor, this suggests a relationship between VEGF
expression and invasion of the vascular wall. Indeed,
V E G Fm a yi n d u c eab r e a k d o w no fv a s c u l a rw a l l sb y
inducing protease synthesis which may result in dama-
ging vascular structures [49].
The current investigation revealed a significant
decrease in serum VEGF level in silymarin supplemen-
ted rats compared to NDEA treated animals. Our results
are in accordance with Jiang et al. [50] who reported
that silymarin has antiangiogenic activity that may con-
tribute critically to its cancer chemopreventive potential.
The antiangiogenic effect of silymarin might be attribu-
ted to its rapid inhibitory action on the secretion of the
primary angiogenic cytokine VEGF by the cancer epithe-
lial cells. Also, silymarin inhibited endothelial matrix
metalloproteinase-2 (MMP-2) secretion and expression,
thus silymarin may provide an inhibitory mechanism on
angiogenesis independent of its effect on VEGF [51].
Additionally, silybin (the main active constituent of sily-
marin) decreased the expression of hypoxia inducible
factor-1a (HIF-1a) and inducible nitric oxide synthase
(iNOS) that induce angiogenesis [52]. The current inves-
tigation also revealed a significant decrease in serum
VEGF level in EGb supplemented rats compared to
NDEA treated animals. Recent study demonstrated the
requirement for the extracellular signal-regulated kinase
(ERK) in growth factor induced angiogenesis. It has
been shown that EGb reduces ERK phosphorylation
induced by the growth factors VEGF and fibroblast
growth factor (FGF) in an endothelial cell model leading
to the suggestion that EGb inhibits angiogenesis via
ERK inhibition as EGb activates protein tyrosine phos-
phatases [53]. It has been also shown that EGb inhibits
the ‘’respiratory (oxidative) burst’’ that results from the
activation of human neutrophils, an action that could be
associated with antiangiogenic and antitumorigenic
activities because activated human neutrophils have
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VEGF and hepatocyte growth factor/scatter factor, two
cytokines that have potent proangiogenic properties
[54,55].
T h ec o m e ta s s a y( S C G E )i sar a p i d ,s e n s i t i v ea n dv e r -
satile method for the quantification of DNA damage in
the individual cells both in vitro and in vivo [56]. In
the comet assay, cells with damaged DNA displayed
increased migration of DNA fragments (comet tail)
from the nucleoid (comet head) which may also be a
feature of DNA fragmentation associated with the
necrotic/apoptotic death process [57]. The current
investigation demonstrated a highly significant increase
in the comet assay parameters (TL,% DNA in tail and
TM) in NDEA treated rats compared to the healthy
control rats. This is in consistent with the previous
results of H o r s te ta l .[58] who reported NDEA-
induced DNA damage indicated by the markedly
increased length of the comets (head + tail) in the
liver cells of rats administrated NDEA compared to
the negative control rats. The increment of such para-
meters may be due to that the enzymes of CYP2E1
s u b f a m i l yp l a yar o l ei nt h eb i o t r a n s f o r m a t i o no fa
range of compounds, including NDEA, producing the
promutagenic DNA lesions which play an important
role in DNA damage and induction of hepatocarcino-
genesis [35].
Silymarin supplementation in our study was effective
in suppressing DNA damage induced by NDEA showing
a significant decrease in the comet assay parameters
(TL,% DNA in tail and TM) compared to NDEA treated
group. These results were consistent with Saravanan
and Pugalendi [59] who reported that the coadminis-
tration of silymarin with alcohol significantly decreased
the DNA damage when compared with alcohol treated
rats. This protective effect of silymarin can be explained
by its ability to scavenge the free radicals before they
cause damage to nuclear DNA [60]. Ginkgo biloba
extract supplementation in our study significantly
diminished DNA damage caused by NDEA as indicated
by a significant decrease in the comet assay parameters
(TL,% DNA in tail and TM) compared to NDEA treated
group. This was attributed to that EGb is cytoprotective;
it is able to permeate cell membranes and exert its pro-
tective action on the nuclear DNA and also cytoplasmic
components [61]. Keles et al. [62] reported that pre-
treatment with EGb clearly diminished 8-hydroxydeoxy-
guanosine (8-OHdG) formation in DNA in the hepatic
tissue of rats that had undergone liver ischaemia-reper-
fusion (IR). This protective effect of EGb has been
attributed to its high free radical scavenging ability. Min
and Ebeler [63] suggested the potential of quercetin
(the major component of flavonoid glycosides of EGb)
to protect against cancer by inhibiting oxidative DNA
damage as well as by enhancing DNA repair after oxi-
dant challenge in Caco-2 cells (colon cells).
Serum AST and ALT are the most sensitive markers
employed in the diagnosis of hepatic damage because
they are cytoplasmic in location and hence released into
the circulation after cellular damage. Analysis of these
marker enzymes reflects mechanisms of cellular damage,
subsequent release of proteins, their extracellular turn-
over and mechanisms of neoplastic processes [64]. GGT
is an enzyme embedded in the hepatocyte plasma mem-
brane mainly in the canalicular domain and its libera-
tion into serum indicates damage to the cell, thus injury
to the liver [65]. The present study demonstrated that
activities of ALT, AST and GGT in the sera of NDEA
treated rats were markedly elevated compared to the
normal healthy control rats. This increment is due to
the production of free radicals during NDEA metabo-
lism, thus damaging the hepatocellular membrane. As a
result, these cytoplasmic enzymes are released into the
systemic circulation.
As seen in the present study, treatment with silymarin
significantly reduced serum ALT, AST and GGT activ-
ities compared to NDEA treated animals. This might be
attributed to the ability of silymarin to scavenge the free
radicals, thus preventing the hepatocellular damage
caused by NDEA, thereby suppressing the leakage of
enzymes through plasma membranes [11]. Supplementa-
tion of EGb to HHC-induced animals effectively lowers
the high serum activities of AST, ALT and GGT pro-
duced by NDEA. This hepatoprotective effect of EGb
could be due to a modifying influence on the biotrans-
formation/detoxification of NDEA, thus reducing its
liver toxicity [66].
The biochemical findings in our study were supported
by the histopathological examination of the liver tissue
of experimental animals. The histopathological observa-
tion of the livers of NDEA treated rats revealed well dif-
ferentiated HCC with disorganization of hepatic lobular
architecture and obvious cellular damage. The hepato-
cytes exhibited megalocytosis, foamy cytoplasm and
hyperchromatic nuclei. This is in agreement with the
results of Gupta et al. [67] who reported that the histo-
logical examination of the liver tissue of rats treated
with NDEA revealed vacuolization, loss of normal hepa-
tocellular architecture and the presence of pycnotic
nuclei. This may be attributed to that NDEA is primar-
ily metabolized in the liver and reactive metabolites gen-
erated thereby are known to damage hepatocytes.
Histopathology of the liver tissue of rats pretreated
with silymarin revealed an improvement in the hepato-
cytes exhibiting less disarrangement and degeneration of
hepatocytes compared to NDEA treated rats. Liver sec-
tions of rats posttreated with silymarin revealed a slight
improvement in the hepatocytes exhibiting lesser degree
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nuclear vesiculation and prominence compared with
NDEA treated group. This improvement may be attribu-
ted to that silymarin can efficiently reduce intracellular
ROS levels of hepatocytes, thus preventing oxidative
stress-induced cellular damage. Furthermore, hepatic
cell proliferation was found to be stimulated after sily-
marin treatment suggesting that enhanced liver regen-
eration may help replace the damaged liver cells [12].
Liver sections of rats pretreated with EGb revealed an
improvement in the hepatocytes exhibiting less disar-
rangement and degeneration of hepatocytes compared
with NDEA treated group. The liver sections of rats
posttreated with EGb revealed a slight improvement in
the hepatocytes exhibiting lesser degree of vacuolated
hepatocytes and kupffer cells activation compared with
NDEA treated group. These beneficial effects of EGb
can be partially explained by its antioxidant properties
and by inhibition of CYP2E1 that metabolizes NDEA in
the liver [35].
Our study revealed that pretreatment with silymarin
and Ginkgo biloba extract presented more protection of
liver against NDEA induced damage than posttreatment
with these extracts. Therefore, the chemopreventive
activities of silymarin and Ginkgo biloba extract during
initiation stage are more effective than post-initiation
stage of rat hepatocarcinogenesis induced by NDEA. In
conclusion, this study demonstrated that silymarin and
Ginkgo biloba extract have been found to possess a ben-
eficial protective effect against NDEA-induced hepato-
carcinogenesis through their antioxidant, antigenotoxic
and antiangiogenic activities. From this, we can hypothe-
size that these extracts are strong candidates as chemo-
preventive agents for liver cancer.
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